Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report identifies a novel AR gene mutation in an adolescent with primary amenorrhea, suggesting that CAIS should be considered when evaluating patients with a female phenotype and breast development.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

This study investigates the role of retinoic acid in regulating hair follicle stem cell homeostasis to identify new potential targets for treating androgenetic alopecia.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This article reviews the discovery and various physiological effects of cyproterone acetate, reporting its established indications for several androgen-driven conditions but providing no new clinical data.

This abstract contains no research findings but is a snippet of a website interface for JAMA Dermatology.

This study found evidence of structurally and functionally distinct AR-SARM protein complexes, which may contribute to understanding how SARMs achieve tissue-selective effects.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that Aminexil clinical 5 significantly reduced hair loss in men and women with mild alopecia and was well tolerated with high subject satisfaction.

This case report describes a 9-year-old boy with atypical alopecic and aseptic nodules of the scalp, suggesting possible inclusion within the spectrum of typical AANS and DCS due to its prepubertal onset and facial involvement.

In this case series, researchers reported an unexpectedly rapid and positive response to a topical, hydrogel-based botanical treatment for androgenetic alopecia in both male and female volunteers, achieving significant improvement in hair loss within 90 days instead of the planned 270 days.

Reduced AhR signaling in HS tunnels leads to persistent inflammation and microbial imbalance.

In this study, eight patients with hereditary vitamin D-resistant rickets who share a specific VDR mutation showed improved clinical symptoms except alopecia after up to 11 years of treatment.

This study aimed to determine if MRI can assess anatomical changes in the scalp caused by androgenetic alopecia, but it reports no new clinical results.

In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.

This case report highlights a rare presentation of APS-1 in a 28-year-old Pakistani male with cardiovascular and pulmonary symptoms, illustrating the importance of early recognition and multidisciplinary management for improved patient outcomes.

This research found that topical minoxidil may promote hair regrowth in alopecia areata by stimulating hair follicle epithelium and suppressing certain immune responses, with potential contributions from its vasodilatory effects.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This case report suggests that in African-American patients, the histology of Central Centrifugal Cicatricial Alopecia may resemble lichen planopilaris, indicating a potential diagnostic challenge.

This study reports three cases of alopecia areata resistant to corticosteroids that improved after 16 weeks of treatment with a combination of fractional carbon dioxide laser and topical tacrolimus, suggesting a potential new therapeutic option that requires further confirmation.

This study found that patients with rosacea had significantly more radiological evidence of chronic rhinosinusitis, and erythematotelangiectatic severity was associated with CRS.

This study reports two cases where acquired perforating dermatosis was localized to the scalp and coincided with acute diffuse alopecia, suggesting perifollicular inflammation may link the two conditions.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

This study reported that while Intralesional Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, it also led to symptoms of Cushing's Syndrome, highlighting the need for careful monitoring of adverse effects.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This case report describes a patient with both rheumatoid arthritis and alopecia areata who showed improvement in both conditions after treatment with baricitinib monotherapy, highlighting the importance of personalized treatment approaches in managing co-occurring autoimmune diseases.